Zenas BioPharma (ZBIO) Retained Earnings (2023 - 2026)

Zenas BioPharma's Retained Earnings history runs 4 years deep, the most recent figure standing at -$846.1 million for Q1 2026.

• In Q1 2026, Retained Earnings fell 600181.56% year-over-year to -$846.1 million; the TTM figure through Mar 2026 stood at -$846.1 million (down 600181.56% YoY), while the FY2025 annual figure was -$64000.0, down 132.99% from the prior year.
• Retained Earnings was -$846.1 million for Q1 2026 at Zenas BioPharma, down from -$64000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $194000.0 in Q4 2024 to a low of -$846.1 million in Q1 2026.
• Historically, Retained Earnings has averaged -$301.1 million across 4 years, with a median of -$282.6 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Retained Earnings jumped 100.08% in 2024, then plunged 600181.56% in 2026.
• A 4-year view of Retained Earnings shows it stood at -$230.4 million in 2023, then soared by 100.08% to $194000.0 in 2024, then plunged by 132.99% to -$64000.0 in 2025, then sank by 1321954.69% to -$846.1 million in 2026.
• The last three Retained Earnings figures came in at -$846.1 million (Q1 2026), -$64000.0 (Q4 2025), and -$524.7 million (Q3 2025), per Business Quant data.